Analysis of Morbidity Dynamics and Factors Influencing the Development of Pneumococcal Infections among the Adult Population of the Sakha Republic (Yakutia)
https://doi.org/10.31631/2073-3046-2018-17-4-38-45
Abstract
The pneumococcal infection is an important issue due to its prevalence, numerous severe complications, high mortality rate and disability. However modern vaccination allows preventing of the pneumococcal infection and reduces the severity of clinical complications. This article presents the analysis of the morbidity and mortality indicators from community-acquired pneumonia and the effect of pneumococcal vaccination on its dynamic in the at-risk groups within the adult population of the Aldan area and the city of Aldan of the Sakha Republic (Yakutia). In the Aldan area pneumonia morbidity persistently exceeds the national Russian average: in 2015 – 1.5 times (499.3 per 100,000 population) and in 2016 – 1.2 times (500.8 per 100,000 population). The morbidity indicators in Aldan are comparable to the national values. The community-acquired pneumonia mortality rates in the Aldan area were 20.55 per 100,000 population in 2015, and 18.5 per 100,000 population in 2016; these values are, respectively, 4.3 and 3.8 times higher than the national average. In the city of Aldan the community-acquired pneumonia mortality rates were 9.87 per 100,000 population in 2015 and 15.8 per 100,000 population in 2016, which is more than double the national average in the Russian Federation. Pneumococcal vaccinations of the adult population using the conjugate vaccine Prevenar 13 have been observed to lower the pneumonia morbidity and respiratory infections; the vaccinations also reduced the number of hospitalizations due to condition exacerbations or decompensations among adult patients with chronic lung disorders, cardiac insufficiency, and diabetes.
About the Authors
A. N. ArgunovaRussian Federation
Agrafena N. Argunova – Cand. Sci. (Med.), associate professor of the Department of Hospital Therapy, Occupational Diseases and Clinical Pharmacology
Yakutsk, st. Stadukhina, 81
Zh. V. Bondareva
Russian Federation
Zhanna V. Bondareva – Cand. Sci. (Med.), associate professor of the Institute of Therapy and Instrumental Diagnostics
Vladivostok
E. S. Prokopiev
Russian Federation
Egor S. Prokopiev – chief specialist-therapist
Yakutsk
O. М. Nosikhina
Russian Federation
Oksana M. Nosikhina – deputy on the medical part of the chief doctor
Aldan
References
1. Baranov A. A., Briko N. I., Namazova-Baranova L. S. Contemporary clinico-epidemiological characteristic of the pneumococcal infections. Lechashchiy vrach [Therapist]. 2012; 4: 79–83 (in Russian).
2. Vaccine Prophylaxis for Pneumococcal Infection. Federal’nyye klinicheskiye rekomendatsii [Federal clinical guidelines]. Moscow; 2015 (in Russian).
3. World Health Organization (WHO). The top 10 causes of death. February 2016.
4. World Health Organization (WHO). 10 facts on immunization. April 2012.
5. Moberley S., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 2013; 1: CD000422.
6. Pneumococcal conjugate vaccine for childhood immunization – WHO position paper. Weekly Epidemiological Record, 2007; 82 (12): 93–104.
7. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2014–2015. Morb. Mortal. Wkly Rep. 2014; 63 (32); 691–697.
8. Ilyina S. V., Beletskaya O. A., Sabitov A. U.. The efficiency and safety of using pneumococcal conjugate vaccines in the Russian Federation. Epidemiologiya i infektsionnyye bolezni [Epidemiology and Infectious Diseases]. 2013; 6: 55–59 (in Russian).
9. Vos Q, Lees A, Wu ZQ, Snapper C.M., Mond J.J. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms.Immunol Rev 2000; 176: 154–70.
10. Ignatova G. L., Antonov V. N., Rodionova O. V. The effectiveness of using the conjugated pneumococcal vaccine in patients with chronic obstructive pulmonary disease for 3 years. Consilium Medicum. 2016; 18 (3): 42–46 (in Russian).
11. Kostinov M. P., Chuchalin A. G., Korovkina Ye. S. The innovative vaccine against pneumococcus infection as prevention of exacerbations of chronic diseases in adults. Zdravookhraneniye Rossiyskoy Federatsii [Health of the Russian Federation]. 2015; 59 (5): 49–53 (in Russian).
12. Grigorieva E. A., Kir’yantseva L. P. Weather as a risk factor in respiratory morbidity and preventive measures among students. Byulleten’ fiziologii i patologii dykhaniya [Bulletin of the Physiology and Pathology of Breathing]. 2014; 51: 62–68 (in Russian).
13. Lutsenko M.T., Pirogov A.B. Chronic respiratory diseases in conditions of North Russia. Fundamental’nyye Issledovaniya [Basic Research]. 2012; 4–1: 74–79 (in Russian
Review
For citations:
Argunova A.N., Bondareva Zh.V., Prokopiev E.S., Nosikhina O.М. Analysis of Morbidity Dynamics and Factors Influencing the Development of Pneumococcal Infections among the Adult Population of the Sakha Republic (Yakutia). Epidemiology and Vaccinal Prevention. 2018;17(4):38-45. (In Russ.) https://doi.org/10.31631/2073-3046-2018-17-4-38-45